Splanchnic vein thrombosis associated with SARS-CoV-2 infection: A VALDIG case-control study.
Portal vein thrombosis
SARS-CoV-2 infection
Splanchnic vein thrombosis
Journal
JHEP reports : innovation in hepatology
ISSN: 2589-5559
Titre abrégé: JHEP Rep
Pays: Netherlands
ID NLM: 101761237
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
02
06
2023
revised:
28
07
2023
accepted:
14
08
2023
medline:
16
10
2023
pubmed:
16
10
2023
entrez:
16
10
2023
Statut:
epublish
Résumé
Whether severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is a risk factor for splanchnic vein thrombosis (SVT) is unknown. This study aims to assess the impact of SARS-CoV-2 infection on the presentation and prognosis of recent SVT and to identify specific characteristics of SARS-CoV-2-associated SVT. This is a retrospective study collecting health-related data of 27 patients presenting with recent SVT in the context of SARS-CoV-2 infection in 12 Vascular Liver Disease Group (VALDIG) centres and in comparison with 494 patients with recent SVT before the SARS-CoV-2 pandemic. Twenty-one patients with SARS-CoV-2 had portal vein thrombosis with or without thrombosis of another splanchnic vein, two had superior mesenteric vein thrombosis, one had splenic vein thrombosis, and three had hepatic vein thrombosis. Diagnosis of SVT was made 10 days (95% CI 0-24 days) after the diagnosis of SARS-CoV-2 infection. Fever (52 SARS-CoV-2 infection can be associated with recent SVT. Intestinal infarction leading to intestinal resection might be more frequent in patients with SARS-CoV-2. SARS-CoV-2 infection can be associated with recent SVT. SVT occurring during SARS-CoV-2 infection is characterised by a higher frequency of respiratory symptoms and a lower lymphocyte count. Intestinal infarction leading to intestinal resection appears to occur more frequently in patients with SARS-CoV-2.
Sections du résumé
Background & Aims
UNASSIGNED
Whether severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is a risk factor for splanchnic vein thrombosis (SVT) is unknown. This study aims to assess the impact of SARS-CoV-2 infection on the presentation and prognosis of recent SVT and to identify specific characteristics of SARS-CoV-2-associated SVT.
Methods
UNASSIGNED
This is a retrospective study collecting health-related data of 27 patients presenting with recent SVT in the context of SARS-CoV-2 infection in 12 Vascular Liver Disease Group (VALDIG) centres and in comparison with 494 patients with recent SVT before the SARS-CoV-2 pandemic.
Results
UNASSIGNED
Twenty-one patients with SARS-CoV-2 had portal vein thrombosis with or without thrombosis of another splanchnic vein, two had superior mesenteric vein thrombosis, one had splenic vein thrombosis, and three had hepatic vein thrombosis. Diagnosis of SVT was made 10 days (95% CI 0-24 days) after the diagnosis of SARS-CoV-2 infection. Fever (52
Conclusions
UNASSIGNED
SARS-CoV-2 infection can be associated with recent SVT. Intestinal infarction leading to intestinal resection might be more frequent in patients with SARS-CoV-2.
Impact and implications
UNASSIGNED
SARS-CoV-2 infection can be associated with recent SVT. SVT occurring during SARS-CoV-2 infection is characterised by a higher frequency of respiratory symptoms and a lower lymphocyte count. Intestinal infarction leading to intestinal resection appears to occur more frequently in patients with SARS-CoV-2.
Identifiants
pubmed: 37841638
doi: 10.1016/j.jhepr.2023.100894
pii: S2589-5559(23)00225-2
pmc: PMC10570588
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100894Informations de copyright
© 2023 The Author(s).
Déclaration de conflit d'intérêts
The authors have no competing interests to declare. Please refer to the accompanying ICMJE disclosure forms for further details.
Références
Dig Liver Dis. 2021 Aug;53(8):937-949
pubmed: 34120860
Am J Gastroenterol. 2020 Sep;115(9):1545-1546
pubmed: 32694290
Hepatology. 2010 Jan;51(1):210-8
pubmed: 19821530
Dig Liver Dis. 2020 Dec;52(12):1407-1409
pubmed: 33067157
Am J Case Rep. 2020 Sep 24;21:e926785
pubmed: 32970653
J Gastroenterol Hepatol. 2020 Nov;35(11):1853
pubmed: 32839984
J Am Coll Cardiol. 2020 Jun 16;75(23):2950-2973
pubmed: 32311448
Hepatology. 2021 Apr;73(4):1521-1530
pubmed: 32692464
Am J Gastroenterol. 2020 Jul 1;115(7):1140-1142
pubmed: 32618673